Aim: To present a case of catatonia on exposure to quetiapine. Clinical details: We report the case of a 68-year-old man with bipolar affective disorder who experienced catatonia upon initiation of quetiapine on day 4 of his admission to hospital. He was commenced on quetiapine 50 mg at night which was increased to 100 mg the following night. He did not have a prior history of any reaction to the medication. Outcome symptoms: Resolved upon discontinuation of quetiapine. Conclusion: The importance of pharmacovigilance cannot be overemphasised. Clinicians need to be aware that catatonia may occur with the use of quetiapine and patients need to be closely monitored for unexpected reactions.
INTRODUCTION
Catatonia is defined as a behavioural syndrome where an individual is not able to move normally, even though they have the complete physical capacity to do so. While apparently conscious, the individual is unresponsive to external stimuli. 1 Three types of catatonia are:
retarded, excited and malignant. Possible symptoms can range from immobility, mutism and staring, to excessive purposeless motor activity and echophenomena. 2 It is important to identify the cause of the catatonia in order to find a resolution as soon as possible, particularly if antipsychotics which can cause movement disturbances are involved. 3, 4 Catatonia can be life-threatening and needs to be quickly identified and treated.
CASE DESCRIPTION
A 68-year-old Caucasian man, weight 70.6 kg, with a diagnosis of bipolar affective disorder (BPAD) was admitted to the Acute Mental Health Unit of Maryborough Hospital with depression and suicidal ideation. He had no history of substance abuse and was taking nil regular medications prior to admission. Upon admission, he was commenced on citalopram 10 mg daily on day 1 which was increased to 20 mg on day 5. Quetiapine (immediate release) tablet 50 mg every night was added on day 4 for depression and insomnia. Quetiapine was then increased to 100 mg every night on day 5. The following morning (day 6) at 09:30 hours he was observed by the nurses to be lying flat on his back with arms by his side, staring at the ceiling. Asked if he was okay, the patient responded: 'I can't move'. He was immediately reviewed by the treating team who noted that he was unresponsive to voice and pain. Pupils equal and reactive to light (PEARL) were sluggish, plantar reflex was absent and other reflexes were brisk. Upper and lower limbs were alternately limp but mostly stiff. No cogwheel rigidity was observed. Observations were all normal, including blood pressure, respiratory rate and temperature. The plan was to check his creatine kinase level, C-reactive protein, full blood count, urea and electrolytes and liver function, which all came back normal as evident in Table 1 .
Quetiapine was ceased. Lorazepam 1 mg was administered immediately by intramuscular injection at 09:50 hours. Respiration rate was 28 and shallow, other vital signs were not significant but constant observation continued. At 11:00 hours, he was observed to be lying in bed and groaning; a second dose of intramuscular lorazepam 1 mg was given. He was then commenced on lorazepam 1 mg orally three times a day. A second psychiatric opinion at 12:30 hours found the patient seated on his bed, alert and oriented. He had a logical thought process and his affect was full and appropriate. The impression was resolution of an acute catatonic episode following medication.
DISCUSSION
The incidence of catatonia has primarily been assessed in acute psychiatric settings where it is most commonly seen. The incidence is approximately 10%; however, can range between 5-20%. 1 The incidence of drug-induced catatonia is unknown. 5 The symptoms of catatonia, if only short-term, may go unnoticed and this can lead to a false conclusion that this syndrome is rare. Furthermore, over the years the management of mental illness has largely changed from an institutionalised setting to an outpatient setting and this often results in reactions not being as frequently reported. 6 Although there is no specific risk factor for catatonia, it seems to be more prevalent in individuals with depressive disorder or BPAD. 7 It can also be associated with psychotic disorders such as schizophrenia, as well as autism spectrum disorder. Medications used in the treatment of these medical conditions, such as antipsychotics, can cause or worsen catatonia. 2, 7 Studies have shown that this syndrome may involve pathways connecting the basal ganglia with the cortex and thalamus. It has been proposed that the likely abnormality is in the c-aminobutyric acid-A receptors, resulting in hypoactivity of this neurotransmitter in cortical areas and hypo-activity of dopaminergic transmission in subcortical areas. When assessing a patient for catatonia, it is important to take a full mental status and physical examination, psychiatric and general medical history. In addition to this, laboratory tests can guide findings of the physical examination including, in more serious cases, the possibility of leukocytosis, increased creatine kinase, and low serum iron. 3 Gathering a correct diagnosis is essential and differential diagnoses that must be ruled out include neuroleptic malignant syndrome (NMS), serotonin syndrome, malignant hyperthermia and Parkinson's disease. 5 As per the Diagnostic and Statistical
Manual 5 th edition, catatonia is defined as the presence of three or more of the following: stupor, catalepsy, waxy flexibility, mutism, negativism, posturing, mannerism, stereotypy, agitation, grimacing, echolalia, echopraxia. 6 In this case, the individual experienced catalepsy, stupor and mutism. First-line management of catatonia is administration of a benzodiazepine or electroconvulsive therapy depending on severity. Lorazepam has been studied most frequently, but other benzodiazepines can also be used. The intravenous route of administration is preferred to ensure rapid absorption, as well as permitting administration of rehydration fluids if needed. 1, 4 In this case, risk factors for catatonia include the fact that he suffered from BPAD, but also that he was prescribed quetiapine. Although antipsychotics have been implicated in numerous cases of movement disturbance including catatonia, 5 it is important to note that worsening of BPAD, which necessitated the initiation and subsequent increased dose of quetiapine, may be the cause of catatonia. In addition to the relatively low dose that was prescribed, quetiapine is one of the suitable antipsychotics in patients with neurological disorders. 8 However, because the patient had no previous history of catatonia and he had an increased dose of quetiapine about 10-12 h prior, catatonia was thought to be due to quetiapine. Quetiapine antagonises serotonin 5HT 1a and 5HT 2 , dopamine D 1 and D 2 , histamine H 1 , and adrenergic alpha 1 and alpha 2 receptors. Due to the pharmacokinetic properties of antagonism with higher selectivity for 5HT 2 relative to D 2 receptors, NMS and extra-pyramidal side effects (EPSE) are uncommon in comparison to first-generation antipsychotics. 3 Risk factors for movement disturbance with antipsychotics include using large doses, high potency first-generation antipsychotics, and rapid dose increases. 9, 10 Although it is unlikely that any other medication contributed to catatonia in this 
CONCLUSION
It is important to remember that even though secondgeneration antipsychotics, like quetiapine, are less likely to cause EPSE, there is still risk involved. When prescribing quetiapine, health practitioners need to be aware that this adverse effect may occur and should review their patients for any signs of intolerance. Finally, pharmacovigilance for the possibility of previously unreported adverse events must remain at the core of clinical practice.
